{"id":389975,"date":"2021-09-30T00:00:00","date_gmt":"2021-09-30T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/biosbi0002-2020-biopharma-biosimilars-current-treatment-endocrinology-us-eu-2020\/"},"modified":"2026-03-31T10:42:29","modified_gmt":"2026-03-31T10:42:29","slug":"biosbi0002-2020-biopharma-biosimilars-current-treatment-endocrinology-us-eu-2020","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/biosbi0002-2020-biopharma-biosimilars-current-treatment-endocrinology-us-eu-2020\/","title":{"rendered":"Biosimilars | Current Treatment | Endocrinology | US\/EU | 2020"},"content":{"rendered":"<p>The biosimilar \/ follow-on insulin sector of the diabetes therapy market is evolving. Eli Lilly \/ Boehringer Ingelheim\u2019s Abasaglar \/ Basaglar was the first biosimilar \/ follow-on insulin glargine to launch in Europe and the United States, followed by Sanofi\u2019s Admelog \/ Insulin lispro Sanofi. Subsequently, the EC approved Biocon \/ Mylan\u2019s insulin glargine biosimilar, Semglee, which the FDA approved in June 2020.<\/p>\n<p>The prescribing behavior of endocrinologists will directly impact the uptake of these products, including insulin brands such as Sanofi\u2019s Lantus and Eli Lilly\u2019s Humalog. Understanding physicians\u2019 attitude and behavior toward biosimilars \/ follow-on insulins is critical for development and marketing strategies aimed at persuading endocrinologists to prescribe and drive biosimilar \/ follow-on insulin uptake.<\/p>\n<p>DRG\u2019s primary research with endocrinologists in the United States, France, and Germany allows clients to assess the dynamics determining current and future biosimilar \/ follow-on insulin uptake within the diabetes space.<\/p>\n<p>This report\u00a0includes the following topics:<\/p>\n<ul type=\"disc\">\n<li>Physicians\u2019 current experience prescribing biosimilars \/ follow-on insulins.<\/li>\n<li>The main drivers and barriers influencing biosimilar \/ follow-on insulin uptake.<\/li>\n<li>The impact of cost and clinical data on biosimilar \/ follow-on insulin uptake.<\/li>\n<\/ul>\n<p><strong>Scope<\/strong><\/p>\n<p><strong>Markets covered:<\/strong>\u00a0United States, France, and Germany.<\/p>\n<p><strong>Primary research:\u00a0<\/strong>Online quantitative survey of 91\u00a0endocrinologists.<\/p>\n<p><em>Current Treatment: Physician Insights\u00a0<\/em>provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.<\/p>\n","protected":false},"template":"","class_list":["post-389975","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-product-biosimilars","biopharma-product-current-treatment","biopharma-geography-us","biopharma-date-950"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389975","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389975\/revisions"}],"predecessor-version":[{"id":393100,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389975\/revisions\/393100"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=389975"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}